BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 17065593)

  • 1. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
    Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.
    Edison P; Archer HA; Gerhard A; Hinz R; Pavese N; Turkheimer FE; Hammers A; Tai YF; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurobiol Dis; 2008 Dec; 32(3):412-9. PubMed ID: 18786637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
    Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.
    Tolboom N; van der Flier WM; Yaqub M; Koene T; Boellaard R; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    Neurology; 2009 Dec; 73(24):2079-85. PubMed ID: 20018636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.
    Ziolko SK; Weissfeld LA; Klunk WE; Mathis CA; Hoge JA; Lopresti BJ; DeKosky ST; Price JC
    Neuroimage; 2006 Oct; 33(1):94-102. PubMed ID: 16905334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of PIB-PET as a dual pathological and functional biomarker in AD.
    Forsberg A; Engler H; Blomquist G; Långström B; Nordberg A
    Biochim Biophys Acta; 2012 Mar; 1822(3):380-5. PubMed ID: 22115832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.
    Roberts RO; Knopman DS; Cha RH; Mielke MM; Pankratz VS; Boeve BF; Kantarci K; Geda YE; Jack CR; Petersen RC; Lowe VJ
    J Nucl Med; 2014 May; 55(5):759-64. PubMed ID: 24652830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
    Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
    Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions.
    Klupp E; Förster S; Grimmer T; Tahmasian M; Yakushev I; Sorg C; Yousefi BH; Drzezga A
    Brain Connect; 2014 Jun; 4(5):371-83. PubMed ID: 24870443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.
    Park SY; Byun BH; Kim BI; Lim SM; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH
    Medicine (Baltimore); 2020 Apr; 99(16):e19620. PubMed ID: 32311931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
    Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.